With the chronic nature of the condition, cardiovascular diseases not only has long-term clinical consequences but also has a substantial economic burden on both health systems and patients. Across the globe, the health care budget of the countries depends on multiple factors and Health Technology Assessment can guide and assist these critical decisions of health care budgeting especially in the resource-limited settings. Health Technology Assessment is a multidisciplinary area of research that uses evidence related to clinical, cost, context, equity, ethics and social factors for assessing the efficacy of health technology.
Cardiovascular diseases are a global cause of death with approximately 80% of the burden contributed by developing countries. Moreover, in these countries, the disease has started affecting the population at a younger age leaving critical economic burden on the families. Hence, it's imperative to invest wisely in technologies and interventions which can contribute significantly to the prevention and management of the disease and provide economically, socially and contextually acceptable alternatives through systematic, ethical, unbiased, transparent and robust methods of health technology assessment. These evidence-supported approaches can guide policy decisions for both developing and developed economies. The goal is to pave the way for a sustainable health system.
The special issue will cover health technology assessment topics in the field of cardiovascular diseases. The authors are encouraged to submit their studies in the following areas of CVD technologies and programs:
• Partial and full economic evaluations of innovations, medical technologies, programs
• Country specific databases, Reference cases and league tables
• Patients related outcome assessment including quality of life
• Evidence synthesis studies (scoping, systematic reviews and meta-analysis) representing clinical and cost aspects of the innovations
• Methodological approaches related to costing, discounting and inflation
• Health policy, decision making and recommendations
• Ethical, societal, equity and contextual aspects of HTA
With the chronic nature of the condition, cardiovascular diseases not only has long-term clinical consequences but also has a substantial economic burden on both health systems and patients. Across the globe, the health care budget of the countries depends on multiple factors and Health Technology Assessment can guide and assist these critical decisions of health care budgeting especially in the resource-limited settings. Health Technology Assessment is a multidisciplinary area of research that uses evidence related to clinical, cost, context, equity, ethics and social factors for assessing the efficacy of health technology.
Cardiovascular diseases are a global cause of death with approximately 80% of the burden contributed by developing countries. Moreover, in these countries, the disease has started affecting the population at a younger age leaving critical economic burden on the families. Hence, it's imperative to invest wisely in technologies and interventions which can contribute significantly to the prevention and management of the disease and provide economically, socially and contextually acceptable alternatives through systematic, ethical, unbiased, transparent and robust methods of health technology assessment. These evidence-supported approaches can guide policy decisions for both developing and developed economies. The goal is to pave the way for a sustainable health system.
The special issue will cover health technology assessment topics in the field of cardiovascular diseases. The authors are encouraged to submit their studies in the following areas of CVD technologies and programs:
• Partial and full economic evaluations of innovations, medical technologies, programs
• Country specific databases, Reference cases and league tables
• Patients related outcome assessment including quality of life
• Evidence synthesis studies (scoping, systematic reviews and meta-analysis) representing clinical and cost aspects of the innovations
• Methodological approaches related to costing, discounting and inflation
• Health policy, decision making and recommendations
• Ethical, societal, equity and contextual aspects of HTA
